Design biology for sustainable health
Through the in-depth scientific expertise in synthetic biology and data science, we accelerate the discovery and development of safer and more effective therapeutics for patients suffering from various mental illnesses, as well as develop disruptive technology to supply these small-molecule bioactives using scalable and reliable fermentation.
Biomia Secures $3.0 Million in Pre-seed Financing
Biomia secures $3.0 million in pre-seed financing to accelerate the development of its pipeline of plant-inspired natural and new-to-nature halogenated small molecule drug candidates as well as its fermentation-based manufacturing platform and drug discovery engine.
About Biomia
Biomia is a synthetic biology company developing a pipeline of plant-inspired natural and new-to-nature halogenated small molecule drug candidates (Monoterpene Indole Alkaloids (MIAs)) for unmet medical needs in pain, mental health disorders, and addiction. Biomia is a spin-out from the Technical University of Denmark and activities have been funded by the Novo Nordisk Foundation, European Union, and BioInnovation Institute.
Biomia’s unique ability to design and integrate halogenation into the design of the compounds as well as in the state-of-the-art manufacturing platform is expected to generate substantially improved drug candidates with optimized ADME properties and tox profiles, and Biomia aims to develop an internal pipeline MIA drug candidates with well-established links between the MIA targets and the diseases as well as leveraging its platform and discovery engine through partnerships.
Biomia was founded in 2022 by scientists Jie Zhang, Michael K. Jensen, and Jay D. Keasling, and biotech entrepreneurs Sebastian Søderberg and Henrik Stage.
Our unique technology to mimic the nature’s pharmacy, and beyond
Get in touch
Contact form
"*" indicates required fields